Eye fluid test could spot dry AMD changes early
NCT ID NCT07298291
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether taking a tiny sample of fluid from the front of the eye is safe for people with dry age-related macular degeneration (AMD). Researchers will analyze proteins in the fluid to see if they change over time. The study includes 50 adults aged 50 to 89, some with dry AMD and some without. The goal is to see if this simple procedure can help monitor the disease.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- anterior chamber paracentesis (ACP)
- What this could lead to
- If successful, this could lead to a safer, routine diagnostic test to monitor dry AMD progression using eye fluid proteins.
- What could go wrong
- This is a very early safety study with only 50 participants, so it may not confirm the test's usefulness. There is a small risk of eye infection or bleeding from the procedure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2025
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
A research network
The lead sponsor is a research network or cooperative group.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 to 89 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male or female subjects aged between 50 and 89 years, inclusive * For the GA cohort: Clinical diagnosis of GA secondary to AMD or dAMD in the study eye, confirmed by fundus autofluorescence imaging and spectral-domain optical coherence tomography (SD-OCT). * For the control cohort: No clinical evidence of retinal disease in either eye. * Best-corrected visual acuity (BCVA) of ≥20/200 in the study eye, as measured by Early Treatment Diabetic Retinopathy Study (ETDRS) charts * Ability and willingness to provide written informed consent before any study-specific procedures. Exclusion Criteria: * Presence of active ocular infection or inflammation in either eye at the time of screening. * History of intraocular surgery in the study eye within the three months preceding enrollment. * Intraocular pressure (IOP) greater than 21 mmHg in the study eye at screening * Use of systemic anticoagulation therapy that cannot be safely discontinued prior to ACP. * Pregnant or nursing women. * Known hypersensitivity or contraindication to any of the medications or procedures used in the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Age-related (DRY) macular degeneration are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Erie Retina Research
Erie, Pennsylvania, 16505, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.